Lotus Pharmaceutical Co Ltd Total Liabilities
Lotus Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) has total liabilities worth NT$84.28 Billion TWD (≈ $2.66 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 1795 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lotus Pharmaceutical Co Ltd (2009–2025)
Total liabilities of Lotus Pharmaceutical Co Ltd from 2009 to 2025. This chart illustrates how Lotus Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 1795 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Lotus Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lotus Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Great Wall Enterprise Co Ltd
TW:1210
|
Taiwan | NT$40.68 Billion |
|
Dongguan Tarry Electronics Co.Ltd
SHE:300976
|
China | CN¥911.74 Million |
|
Shanghai Pret Composites
SHE:002324
|
China | CN¥8.21 Billion |
|
Adecoagro SA
NYSE:AGRO
|
USA | $3.29 Billion |
|
Hainan Drinda Automotive Trim Co Ltd
SHE:002865
|
China | CN¥13.25 Billion |
|
PDF Solutions Inc
NASDAQ:PDFS
|
USA | $147.68 Million |
|
Hornbach Holding VZO O.N.
XETRA:HBH
|
Germany | €3.07 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Lotus Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 1795 total asset value.
Liquidity & Leverage Metrics
Lotus Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Lotus Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lotus Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lotus Pharmaceutical Co Ltd (2009–2025)
The table below shows the annual total liabilities of Lotus Pharmaceutical Co Ltd from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$82.37 Billion ≈ $2.60 Billion |
+335.36% |
| 2024-12-31 | NT$18.92 Billion ≈ $596.11 Million |
+20.84% |
| 2023-12-31 | NT$15.66 Billion ≈ $493.31 Million |
0.00% |
| 2022-12-31 | NT$15.66 Billion ≈ $493.32 Million |
+54.22% |
| 2021-12-31 | NT$10.15 Billion ≈ $319.88 Million |
-7.76% |
| 2020-12-31 | NT$11.01 Billion ≈ $346.81 Million |
+8.20% |
| 2019-12-31 | NT$10.17 Billion ≈ $320.54 Million |
+41.84% |
| 2018-12-31 | NT$7.17 Billion ≈ $225.99 Million |
-9.91% |
| 2017-12-31 | NT$7.96 Billion ≈ $250.85 Million |
+15.68% |
| 2016-12-31 | NT$6.88 Billion ≈ $216.86 Million |
+1.65% |
| 2015-12-31 | NT$6.77 Billion ≈ $213.33 Million |
-9.22% |
| 2014-12-31 | NT$7.46 Billion ≈ $235.00 Million |
+1354.11% |
| 2013-12-31 | NT$512.97 Million ≈ $16.16 Million |
+14.56% |
| 2012-12-31 | NT$447.79 Million ≈ $14.11 Million |
-14.66% |
| 2011-12-31 | NT$524.73 Million ≈ $16.53 Million |
+6.27% |
| 2010-12-31 | NT$493.75 Million ≈ $15.56 Million |
+97.35% |
| 2009-12-31 | NT$250.19 Million ≈ $7.88 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more